Lilly Alzheimer's drug shows benefit on cognition, function in mid-stage trial

  • 📰 Reuters
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 97%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Eli Lilly and Co on Saturday said its experimental Alzheimer’s drug slowed the rate of decline in a measure of cognition and function by 32% compared with a placebo in a mid-stage trial of patients at an early stage of the mind wasting disease.

FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar

The ability to carry out activities like dressing and eating is often impacted by Alzheimer’s disease, which reduces cognitive ability like memory and language. Beta amyloid has been a popular target for dozens of experimental Alzheimer’s drugs, all of which have failed so far.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Good news

Turkish Airlines Dhaka Office, Bangladesh Contact Info

When to start the medication? Do you ask the doctor or the accountant? Loss of personal financial management skills precedes other signs of deterioration.

wow

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in HEALTH

Health Health Latest News, Health Health Headlines